Evaxion A/S
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.1% over 5Y.
today you would have $6.93▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $4.77 | $4.22 | $34.30 | $88.75 | |
| P/S | 264.2x | 264.2x | 88.6x | 17806.8x | — |
| P/B | — | 116.7x | — | — | 258.0x |
| EPS | -$1.00 | -$10.00 | -$40.50 | -$49.00 | |
| Profit margin | -316.00% | -102.38% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TXMDTherapeuticsMD, Inc. | $2.16 | — | 0.9x | — | -1.08% | $25M |
| DYAIDyadic International Inc | $0.61 | — | — | — | — | $24.6M |
| ATOSAtossa Therapeutics Inc | $2.58 | — | 1.0x | — | -89.23% | $25.75M |
| TVRDTvardi Therapeutics, Inc. | $1.82 |
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Company description provided by Yahoo Finance.
| -316.00% |
| -30308.22% |
| — |
| ROE | — | -45.23% | — | — | -279.04% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.2x |
| — |
| -126.19% |
| $24.28M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |
| BEATHeartBeam, Inc. | $0.47 | — | 3.2x | — | -328.44% | $26.31M |